Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750086 · ClinicalTrials.gov registry record · Phase 4
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT01750086: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01750086 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01750086, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
Interventions
- DRUG Denosumab Injection
- DRUG Teriparatide 40-mcg subcutaneous injection
- DRUG Alendronate Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750086
The ClinicalTrials.gov registry entry for NCT01750086 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Denosumab Injection is the first listed.
NCT01750086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01750086 about?
NCT01750086 is a clinical study titled "Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption". The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
What is the current status of trial NCT01750086?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2013-01. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01750086?
The interventions under investigation include: Denosumab Injection (DRUG), Teriparatide 40-mcg subcutaneous injection (DRUG), Alendronate Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT01750086?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.